RxDoctor Payments Data

April Smith

Gerontology · Lincoln, NENPI 1346605557

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,781in general payments, 2019–2025

Across 299 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$866
  • Alkermes, Inc.$825
  • Otsuka America Pharmaceutical, Inc.$404
  • Corium, LLC$318
  • Axsome Therapeutics, Inc.$254
  • Jazz Pharmaceuticals Inc.$228
  • plus $886 from 19 others

What the payments were for

  • Food & beverage$3,765100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,781 in reported general payments places this provider in the 95th percentile of 21 gerontology providers in Nebraska.

See all gerontology providers in Nebraska

Medicare billing

Part B allowed, 2024
$33,574
Medicare patients
142
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil11$40,054
VraylarCariprazine Hcl23$33,344
EliquisApixaban37$17,877
FarxigaDapagliflozin Propanediol12$17,508
XareltoRivaroxaban34$13,968
JardianceEmpagliflozin32$13,257
Aripiprazole66$11,791
VascepaIcosapent Ethyl23$4,108
Gabapentin108$3,437
Divalproex Sodium ErDivalproex Sodium39$2,452
Quetiapine Fumarate ErQuetiapine Fumarate13$2,138
Atorvastatin Calcium129$2,067
Quetiapine Fumarate79$1,769
Levothyroxine Sodium224$1,706
Duloxetine Hcl61$1,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$825$40,05411 claims
AbbVieVraylar$24$33,34423 claims
PfizerEliquis$41$17,87737 claims
Johnson & JohnsonXarelto$39$13,96834 claims
Almatica Pharma LLCSertraline Hcl$21$98470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 gerontology providers in Nebraska.

Other gerontology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →